NVDA
NVIDIA
-- 133.230 TSLA
Tesla
-- 403.310 DJT
Trump Media & Technology
-- 42.910 AMD
Advanced Micro Devices
-- 117.320 RGTI
Rigetti Computing
-- 6.0500 
NEWS
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
C4 Therapeutics (Nasdaq: CCCC) announced the release of an abstract containing clinical data from its ongoing Phase 1 trial of CFT1946, a novel BiDAC™ degrader, for mutant BRAF V600 solid tumors.
The abstract, with a data cut-off of April 12, 2024, is available on the ESMO Congress 2024 website. An oral presentation scheduled for September 13, 2024, will provide updated data on 36 patients with a cut-off date of July 19, 2024.
The presentation will include patient demographics, safety, pharmacokinetic, pharmacodynamic, and anti-tumor activity data measured by RECIST 1.1 criteria. C4T will host a webcast for analysts and investors on September 13, 2024, at 12:00 pm ET to discuss the findings.
The presentation will include patient demographics, safety, pharmacokinetic, pharmacodynamic, and anti-tumor activity data measured by RECIST 1.1 criteria. C4T will host a webcast for analysts and investors on September 13, 2024, at 12:00 pm ET to discuss the findings.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
6235
Followers
43
Following
67K
Visitors
Follow
Discussing
Trump 2.0 countdown: What's the next big opportunity in the markets?
🎙️️ Discussion: 1. Could Trump's cryptocurrency policies potentially benefit the crypto market? 2. Might his tariff policies have a positiv
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day